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Abstract
Background: High serum levels of cholesterol, in particular low-density lipoprotein cholesterol, are considered a
significant risk factor for development of cardiovascular disease. Therefore, rigorous treatment regimens with statins
and other pharmaceuticals have been used extensively to reduce elevated cholesterol levels. Literature data have
not clearly concluded whether long-chain omega-3 fatty acids reduce, increase or leave circulating cholesterol
unaffected. In the present study a novel krill-oil derived preparation of omega-3 rich phospholipids, mainly
phosphatidylcholine, was administered orally at increasing doses for 12 weeks to dyslipidemic non-human primates,
and cholesterols and several other risk factors for cardiovascular disease were measured before, during and after
treatment.
Methods: Six dyslipidemic non-human primates suffering from naturally occurring diabetes type-2 were included,
three in a vehicle control group and three being treated with the omega-3 rich phospholipid preparation. The
control and test items were given daily by gavage and the doses of the test item were 50, 150 and 450 mg
phospholipids/kg/day. Each dose level was given for 4 weeks. Plasma concentrations of the omega-3 fatty acids
were measured in connection with change in dose and the omega-3 index in erythrocytes was determined bi-
weekly. Blood lipids, apolipoproteins and diabetes, inflammatory and safety biomarkers were determined either
weekly, biweekly or every 4 weeks. For the blood lipids and apolipoproteins, control-adjusted mean values are
presented while absolute values are presented for the other parameters. Due to the low number of animals in each
group, no statistical analyses were done.
Results: The only detectable effects measured during dosing with the lowest dose were an increase in HDL-
cholesterol and apolipoprotein A1. The intermediate and high doses decreased total cholesterol, LDL-cholesterol,
apolipoprotein B100 and triglycerides and increased HDL-cholesterol and apolipoprotein A1. No effects were seen
on the diabetes and inflammatory markers and on safety biomarkers.
Conclusions: The results indicate that the omega-3 rich phospholipid preparation had a positive impact on
cardiovascular disease risk factors by reducing total cholesterol, LDL-cholesterol and triglycerides and increasing
HDL-cholesterol. These findings justify further investigations of this preparation in animal models of dyslipidemia
and, provided the current findings are confirmed, in human trials.
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Background
Cholesterol is a natural component of mammalian cell
membranes and is essential in this lipophilic barrier be-
tween cells. Lipoprotein complexes, which are composed
of lipids and apolipoproteins, are required to transport
cholesterol and lipids through the bloodstream. This
transport system is crucial for life, but excessive concen-
trations of cholesterol in blood, especially when carried
by low-density lipoproteins (LDLs) or very low density
lipoproteins (VLDLs), can accumulate on the walls of ar-
teries. These accumulated lipoproteins increase the risk
for several cardiovascular diseases like stroke and ische-
mic heart disease including myocardial infarction, one
leading cause of death in Western industrial societies.
Hence, rigorous treatment regimens are often prescribed
for patients diagnosed with elevated blood levels of cho-
lesterols and in particular in the cases where LDL chol-
esterol (LDL-c) is above what is considered normal
levels. For the last decades, inhibitors of the enzyme 3-
hydroxy 3-methylglutaryl Coenzyme-A reductase (HMG
CoA) have been the major treatment for the reduction
of elevated cholesterol levels. These drugs, known as sta-
tins, inhibit HMG CoA and thereby one specific step in
the cascade of cholesterol synthesis in cells and have
proven clinically useful in the prevention of cardiovascu-
lar disease caused by hypercholesterolemia [1]. Recently,
more novel drugs for reduction of circulating choles-
terol, the proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors, have been approved for clinical use.
These new drugs act by reducing the endogenous pro-
duction of PCSK9, which normally binds to the LDL re-
ceptor on hepatocytes and causes its internalization and
lysosomal degradation, resulting in lower cellular con-
centrations of the LDL receptor and consequently a
higher level of circulating LDL [2]. Other novel therapies
for normalization of abnormal levels of circulating cho-
lesterols include cholesteryl ester transfer protein
(CETP) inhibitors like dalcetrapib [3], microsomal trigly-
ceride transfer protein (MTP) inhibitors like lomitapide
[4] and antisense therapy of which mipomersen is an
FDA-approved drug [5].
Long-chain (LC) omega-3 fatty acids, in particular ei-
cosapentaenoic acid (EPA; C20:5n3) and docosahexaenoic
acid (DHA; C22:6n3), have long been assumed to have
beneficial effects on cardiovascular health. Multiple bio-
logical effects known to be involved in the development of
cardiovascular disease have been reported for these fatty
acids, including reduction of blood triglycerides [6], im-
proving endothelial function and reducing arterial wall
stiffness [7, 8], reducing inflammations [9, 10], being anti-
arrhythmic [11], reducing blood pressure [12–14] and re-
ducing overall risk for sudden cardiac death [15]. These
two fatty acids are found only in marine sources like fat
fish (e.g., salmon, mackerel and anchovies), krill and algae,
and have been marketed for years as dietary supplements
and more recently also as pharmaceutical products. The
first approved pharmaceutical containing EPA and DHA
was Omacor (generic name: omega-3-acid ethyl esters),
also marketed by the name Lovaza, which is a preparation
of EPA and DHA as ethyl esters [16]. The FDA-approved
indication for this product is the reduction of triglycerides
in patients having “very high” (>500 mg/dL) plasma trigly-
ceride levels [17]. Following the approval of Omacor/
Lovaza, several omega-3 products have been invented for
this indication and are either on the market or under
development.
LC omega-3 fatty acids occur naturally in fish oil mostly
in the form of triglycerides. An alternative form of omega-
3 s found in nature is as phospholipids, for which a major
source is Antarctic krill (Euphausia suberba), an abundant
krill species found in the Southern ocean. The main
phospholipid in krill oil is phosphatidylcholine [18], an
important source of the nutrient choline which since the
1930s has been known to have effects on how lipids, in-
cluding cholesterol, are handled by the body [19]. Choline
is oxidized to betaine, a methyl donor involved in the me-
tabolism of homocysteine which at elevated concentra-
tions has been associated with an increased risk of
cardiovascular disease [20]. Therefore, phosphatidylcho-
line with a high content of omega-3 fatty acids may pro-
vide several components that potentially can have a
positive impact on risk factors for developing cardiovascu-
lar disease.
There have been conflicting data as to whether LC-
omega-3 fatty acids reduce, increase or leave circulating
cholesterols unaffected. Early studies indicated clear and
beneficial effects of these fatty acids, for example Illing-
worth et al. showed a significant decrease of both total
cholesterol and LDL-c in healthy volunteers fed fish oil
as compared to controls. However, in this study a very
high LC omega-3 dose of 24 g/day was used [21]. More
recent studies, applying lower omega-3 doses, have not
been able to demonstrate similar effects on circulating
cholesterols and for Omacor/Lovaza it has been
published that in parallel with its triglyceride-reducing
effect, a slight increase in LDL-c and high-density lipo-
protein cholesterol (HDL-c) levels is observed [16, 22].
The general consensus in the literature seems to be that
use of moderate doses of EPA and DHA, i.e., in the
range of 0.5–5 g/day, does not reduce LDL-c concentra-
tions in blood, a conclusion also reached by an
Evidence-based Practice Center program under contract
to the Agency for Healthcare Research and Quality
(AHRQ), US Department of Health and Human Services
in a report issued already back in 2004 [23] and updated
recently with the same conclusion [24]. However, a
remaining issue with the published data on LC omega-
3 s and cholesterols is that important factors like dose
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levels, duration of treatment, type of omega-3 prepara-
tions used, EPA/DHA ratio in the dosed products, base-
line cholesterol levels, diet, age and health status of the
subjects as well as compliance with the planned dosing
regimens vary considerably. It is therefore difficult to
conclude uniformly on what effects an optimal and well-
controlled use of an optimal preparation of omega-3
fatty acids could have on cholesterol levels in the most
relevant patient population, i.e., in patients with patho-
logically elevated levels and thus having a significant risk
of developing cardiovascular disease.
The primary objective of the study presented here was
to undertake a first investigation of the long-term effects
of a novel and highly purified phospholipid preparation
rich in EPA and DHA, as well as choline, on blood levels
of total cholesterol, LDL-c, HDL-c and triglycerides in
dyslipidemic animals. The phospholipids in the prepar-
ation used in the study were extracted from krill oil. The
animal model chosen for the study were cynomolgus
monkeys with naturally occurring diabetes type-2 which,
as a result of the disease, also had elevated blood lipids.
The model is described in detail in [25] and has shown
to be a relevant model for human disease also in other
aspects of diabetes, like for the development of left ven-
tricular systolic and diastolic dysfunction frequently seen
in diabetic patients [26]. As secondary objectives, we
also investigated if the preparation had effects on dia-
betes markers and markers of inflammation. The safety
of the product was assessed by measuring liver, kidney
and coagulation biomarkers. Plasma and erythrocyte
levels of EPA and DHA were monitored at multiple oc-
casions during treatment.
The data reported in this article originate from a study
which also analyzed the effects of the phospholipid prep-
aration on the time course of erythrocyte membrane
levels of 24 different fatty acids and the time course in
plasma of 6 endocannabinoid-type compounds being
downstream metabolites of some of the fatty acids ana-
lyzed in the erythrocytes. The results of these analyses
will be published separately.
Results
Plasma concentrations of EPA, DHA and DPA
Plasma samples analyzed for EPA and DHA showed that
the concentration of these fatty acids increased with in-
creasing dose (Fig. 1, panels a and b). The mean baseline
concentrations of EPA and DHA in the treated group
were 332 and 4843 ng/ml, respectively. After 4 weeks of
treatment with the low dose of 50 mg/kg/day and just
prior to the increase to the intermediate dose the mean
plasma concentrations had increased to 2233 and
11477 ng/ml. Following completion of treatment with
the intermediate dose of 150 mg/kg/day the mean
plasma concentrations were 6727 and 22400 ng/ml,
respectively, and at the end of the treatment with
450 mg/kg/day the concentrations were 12767 and
20867 ng/ml, respectively. At the end of the 8-week
wash-out period, the EPA and DHA plasma concentra-
tions were 2693 and 12627 ng/ml, respectively. For
DPA, which might be considered a metabolite of EPA,
the mean plasma concentration in the treated group
was 444 ng/ml at baseline, 843 ng/ml at the end of the
low dose treatment, 2277 at the end of the intermedi-
ate dose treatment, 2237 ng/ml at the end of the high
dose treatment and 1196 ng/ml at the end of the
wash-out period (Fig. 1, panel c). In the control group
there was no change in the EPA concentration while
an apparent, slight increase in DPA and DHA concen-
trations was noted during treatment, in particular dur-
ing the period the highest dose was given (Fig. 1,
panels a-c).
Omega-3 index
The relative amount in percent of EPA +DHA in
erythrocyte membranes as compared to the total amount
of fatty acids in the membrane, the so-called omega-3
index [27], increased dose-dependently during the treat-
ment period while no noticeable changes were observed
in the control group (Fig. 1, panel d). At baseline the
index was generally around 5–6% except for one animal
which had an index of 11.2%. The mean baseline omega-
3 index in the control group was 6.0% and in the treated
group 7.1%. The lowest dose, 50 mg/kg/day, increased
the index to a mean of 9.2% during the 4 weeks of dos-
ing, the intermediate dose (150 mg/kg) increased it fur-
ther to 13.1% and the highest dose (450 mg/kg/day) to
18.3% at the end of the 12-week dosing. Following cessa-
tion of dosing the index declined and after 8 weeks with-
out treatment the mean omega-3 index was 8.8%.
Interestingly, this rate of increase and decline is consist-
ent with both EPA and DHA having standard first-order
elimination kinetics.
Further details of the time course of the concentration
of EPA, DHA and 22 other fatty acids in the erythro-
cytes during and after treatment will be published
separately.
Blood lipids and apolipoproteins
The results for the primary parameters, the blood lipids
and the apolipoproteins, are presented in Table 1. The
concentrations of LDL were assessed in three different
ways; LDL-c by the selective-chemically clearing method,
total LDL particles by nuclear magnetic resonance
(NMR) spectroscopy and ApoB100 by immune turbid-
imetry. Concentrations of HDL were assessed in four
different ways; HDL-c by the polymer/detergent method
and by NMR spectroscopy, total HDL particles by NMR
spectroscopy and ApoA1 by immune turbidimetry.
Hals et al. Lipids in Health and Disease  (2017) 16:11 Page 3 of 16
There was a marked variation in baseline values among
the animals but for most of the primary parameters,
higher-than-normal values were measured at start of
treatment. The control-corrected values for the primary
parameters are presented graphically in Fig. 2 and show
that when treated with the intermediate and high dose
levels of the phospholipid preparation, i.e., 150 and
450 mg/kg/day, total cholesterol, non-HDL cholesterol
and LDL-c were dose-dependently reduced. In parallel
to the reduction of LDL-c and LDL particles a reduction
of ApoB100, the main apolipoprotein in LDL [28, 29],
was observed. HDL-c and HDL particles, on the other
hand, were increased during treatment. ApoA1, the prin-
cipal apolipoprotein in HDL [30, 31], also increased al-
though not to the same extent as HDL-c. The size of the
LDL and HDL particles did not change as a result of
treatment with the omega-3 rich phospholipid (Fig. 3).
After cessation of treatment in week 12, both total chol-
esterol and LDL-c concentrations increased towards the
pre-dose levels, while HDL-c concentrations decreased
towards the pre-dose level. This rebound effect further
indicates that the changes in the cholesterols are signifi-
cant effects which are reversible after stopping the treat-
ment and, thus, directly linked to the administration of
the study preparation and the coherent changes in the
omega-3 index. Plasma triglycerides were markedly re-
duced by treatment, most significantly after the highest
dose of 450 mg/kg/day. Treatment did not seem to con-
sistently affect the levels of apolipoproteins ApoB48 or
ApoE, however the levels of ApoC3, an important apoli-
poprotein in VLDL [32, 33], was reduced during the
treatment period although not in a dose-related manner
(Table 2). These three apolipoproteins were not followed





Fig. 1 Mean concentrations of EPA (panel a), DHA (panel b) and DPA (panel c) in plasma and omega-3 index in erythrocytes (panel d) in the control
(dotted lines) and treated (unbroken lines) groups during the 12-week treatment (weeks 0-12) followed by 8 weeks wash-out (weeks 12-20). Vertical lines
indicate SEM for each data-point. Dose-levels at the bottom of the graph refer to phospholipid doses
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2 Panel a: Control-adjusted mean change in total serum cholesterol measured by Siemenes Advia-2400. Panel b: Control-adjusted mean
change of calculated non-HDL cholesterol. Panel c: Control-adjusted mean change of LDL parameters assessed by 3 different methods. 1: LDL-c by
selective chemically clearing method (Siemens Advia-2400); 2: LDL particles by NMR; 3: ApoB100 by turbidimetry (Siemens Advia-2400); 4: the mean of
the three LDL methods. Panel d: Control-adjusted change of HDL parameters assessed by 4 different methods. 5: HDL-c by polymer/detergent method
(Siemens Advia-2400); 6: HDL concentration (calculated) by NMR; 7: HDL particles by NMR; 8: ApoA1 by turbidimetry (Siemens Advia-2400); 9: The mean
results obtained with the four HDL methods. Dose-levels at the bottom of the graph refer to phospholipid doses
Fig. 3 Control adjusted mean values for % change of LDL (unbroken line) and HDL (dotted line) particle size. Dose-levels at the bottom of the
graph refer to phospholipid doses
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Biomarkers of diabetes and inflammation
The treatment with the purified phospholipids had no
noticeable effect on the diabetes-related parameters
glycated hemoglobin (HbA1c), glucose and insulin
(Table 3), which is in line with findings in a meta-
analysis of human studies on effects of omega-3 fatty
acids on diabetes type-2 [34]. Neither was there any
effect on the inflammation markers (data shown in
Additional file 1), however the fact that the C-
reactive protein (C-rp) levels were low at baseline and
throughout the study indicated that the animals had
no on-going systemic inflammation, therefore this
finding was as expected. Having an on-going inflam-
mation was not one of the inclusion criteria, neither
were the animals screened pre-study with respect to
inflammation.
Biomarkers of safety
The results from analysis of the parameters indicative of
effects on liver function, kidney function and co-
agulation are listed in Table 4 and show that the 12-
week treatment with the phospholipids up to 450 mg/
kg/day did not impact any of the liver and kidney bio-
markers, and, furthermore, had no effects on the coagu-
lation parameters monitored. All hematology parameters
remained unchanged throughout the 12-week treatment
period (data shown in Additional file 1). The bodyweight
of all animals was unchanged during the 20 weeks the
study lasted (data shown in Additional file 1).
Discussion
A large number of animal studies on effects of omega-3
fatty acids and other treatment regimens on elevated
blood lipids have been published. The specifics of the
lipid biochemistry in the various species are important
to consider when studies on this topic in animal models
are designed. Commonly used species in this type of re-
search are mice, rats, dogs and pigs, but it is worth not-
ing that none of these species has a blood lipid profile
similar to the profile seen in humans, one important rea-
son being that these species lack or have very low levels
of the cholesteryl-ester transferring protein (CETP), an
enzyme that transfers cholesteryl esters from HDL to
LDL and VLDL [35]. Therefore these species have very
low levels of LDL-c. Species that do express CETP, and
therefore LDL-c levels more similar to humans, include
rabbits, hamsters and non-human primates. According
to Yin et al. (2012), who thoroughly reviewed the rele-
vance of the use of various species in dyslipidemia re-
search, the animal species most likely to predict effects
of lipid-lowering treatment in dyslipidemic humans is
the non-human primate and in particular the rhesus and
cynomolgus strains [36]. The use of non-human pri-
mates in research should be stringently justified due to
their high level of intelligence and sentience [37] but in
order to extract the most predictive and relevant infor-
mation from the current study we decided to use the
cynomolgus monkey as our animal model. Furthermore,
the animals included were suffering from naturally
occurring diabetes type-2, although of such a mild type
Table 3 Mean and SEM values for the monitored diabetes-related parameters Hb1Ac, glucose and insulin in blood from the NHPs at
baseline and during treatment with the omega-3 rich phospholipids. Dose levels of administered phospholipids, EPA, DHA and
choline are given at the end of the table
Parameter Group Value Baseline Week after start of treatment
2 4 6 8 10 12
Hb1Ac (%) Control Mean 9.07 8.60 9.00 9.00 9.37 9.43 9.80
SEM 2.31 2.05 2.35 2.40 2.56 2.69 2.87
Treated Mean 6.63 6.53 6.50 6.40 6.50 6.40 6.67
SEM 1.43 1.64 1.46 1.37 1.23 1.48 1.49
Glucose (mg(dL) Control Mean 195 197 196 182 177 181 203
SEM 64.1 71.8 62.0 61.4 65.8 64.5 71.9
Treated Mean 148 135 157 127 158 119 141
SEM 41.2 31.7 38.3 35.5 30.0 20.0 32.3
Insulin (mIU/mL) Control Mean 33.1 26.3 21.9 46.2 20.9 21.8 28.1
SEM 5.27 5.32 4.86 21.28 5.51 5.61 10.5
Treated Mean 66.7 112 104 91.6 115 74.2 96.7
SEM 29.6 52.1 44.3 40.7 60.5 29.0 54.1
Dose (mg phospholipids/kg bw/day) 50 150 450
Dose (mg [EPA/DHA]/kg bw/day) 9,35/5,48 28,1/16,4 84.2/49.3
Dose (mg choline/kg bw/day) 5,83 17,5 52,5
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Table 4 Mean and SEM values for the safety parameters measured in the control and treated groups at baseline and during the
12 week treatment period. Dose levels of phospholipids, EPA, DHA and choline are given at the end of the table
Parameter Group Value Baseline Week after start of treatment
4 8 12
Alanine transaminase (ALT) (U/L) Control Mean 128 127 182 101
SEM 59 54 103 32
Treated Mean 86 87 65 75
SEM 50 24 2 14
Aspartate Aminotransferase (AST) (U/L) Control Mean 36 32 44 33
SEM 6 4 13 4
Treated Mean 32 27 30 42
SEM 9 5 6 11
Alkaline Phosphatase (ALP) (U/L) Control Mean 225 221 226 220
SEM 37 40 46 56
Treated Mean 162 166 140 169
SEM 37 44 36 68
Blood Urea Nitrogen (BUN) (mmol/L) Control Mean 6.69 6.13 6.46 6.29
SEM 0.46 0.69 0.67 0.69
Treated Mean 6.16 5.65 5.95 5.65
SEM 0.04 0.52 0.63 0.54
Creatinine (μmol/L) Control Mean 62 64 63 61
SEM 23 23 23 23
Treated Mean 77 74 80 76
SEM 5.2 5.6 5.3 5.4
Uric acid (μmol/L) Control Mean 6.07 4.90 5.37 6.40
SEM 0.17 0.12 0.12 0.25
Treated Mean 7.00 9.17 6.70 7.13
SEM 1.04 2.99 1.17 1.33
Cystatin C (mg/L) Control Mean 1.23 1.17 1.15 1.10
SEM 0.21 0.23 0.22 0.16
Treated Mean 1.21 1.23 1.26 1.24
SEM 0.01 0.10 0.10 0.10
Prothromin time (PT) (sec) Control Mean 9.90 9.8 10.5 10.6
SEM 0.36 0.40 0.52 0.64
Treated Mean 10.1 10.0 10.6 10.8
SEM 0.29 0.36 0.32 0.20
Activated Partial Thromboplastin time (APTT) (sec) Control Mean 19.3 19.7 19.1 18.9
SEM 0.18 0.47 0.73 1.22
Treated Mean 21.0 21.9 21.5 21.5
SEM 1.93 1.85 2.18 2.55
Thrombin Time (TT) (sec) Control Mean 30.5 29.8 27.9 26.8
SEM 0.52 1.73 1.54 2.18
Treated Mean 29.3 28.8 28.7 28.1
SEM 0.92 2.80 1.91 1.34
Dose (mg phospholipids/kg bw/day) 50 150 450
Dose (mg [EPA/DHA]/kg bw/day) 9.35/5.48 28.1/16.4 84.2/49.3
Dose (mg choline/kg bw/day) 5.83 17.5 52.5
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that treatment by glucose-lowering therapies was not ne-
cessary. Using animals that were hyperlipidemic because
of a naturally occurring disease was considered more
relevant than a model where the dyslipidemia was in-
duced artificially, e.g., by subchronic feeding with a high
fat or high sucrose diet. However, because of this special
selection of animal model, the number of primates
included was deliberately kept to a minimum in accord-
ance with the 3Rs and as recommended in the Weather-
all report on the use of non-human primates in research
[38]. For the animals included, care and use were con-
ducted in accordance with all applicable assessments
and accreditations of the laboratory animal care (AAA-
LAC) regulations and guidelines and the institutional
animal care and use committee approved all applied pro-
cedures. Furthermore, the animals were not euthanized
at the end of the 20-week in-life phase of the study but
were forwarded into a further wash-out period with the
intention of being used for other studies later. As a
means to compensate for the low number of animals per
group and increase the reliability of the results, the most
important parameters were measured by more than one
method where possible. This was the case for LDL and
HDL as well as for triglycerides.
The main finding in the study presented here was that
the purified, LC omega-3 rich phospholipid preparation
extracted from krill oil reduced total circulating choles-
terol, LDL-cholesterol and triglycerides and increased
HDL-cholesterol when dosed over a 12-week period to
dyslipidemic non-human primates with naturally occur-
ring diabetes type-2. The animals were given escalating
doses of the test and control articles, with each dose
level given daily for 4 weeks. The observed effects were
mostly dose-dependent although the lowest dose, which
was 50 mg phospholipids/kg/day and given during the
first 4 weeks of treatment, had no detectable effect on
total cholesterol and LDL-c, however an apparent in-
crease in HDL and ApoA1 was observed. Triglyceride
levels were also reduced. The lack of effect on total chol-
esterol and LDL-c with the lowest dose could either be
due to the dose being too low or that treatment with this
preparation needs to go on for longer than 4 weeks to
have an effect on these parameters. The intermediate
dose of 150 mg/kg/day, given during weeks 4–8, clearly
reduced total cholesterol, LDL-c and triglycerides and
increased HDL-c and the highest dose of 450 mg/kg/
day, given during weeks 8–12 of treatment, had even
more significant effects on these primary parameters
and proved the potential of this preparation to modify
blood levels of the cholesterols in a health-beneficial pat-
tern. When judging these findings, however, it is import-
ant to keep the study design in mind, particularly the
fact that all three doses were given to the same animals
and that there was a possible accumulation effect.
Hence, the effects observed with the intermediate dose
may have been influenced by the low dose and likewise,
the effects of the high dose may have been influenced by
the low and intermediate doses. From this it is evident
that although the data indicated a dose–response rela-
tionship for most parameters, this relationship should be
interpreted with some caution.
In blood, cholesterol is mostly associated with plasma
lipoproteins, which allow transport around in the body
at concentrations much higher than would otherwise be
possible for lipophilic compounds. The specific lipopro-
teins LDL and HDL are built around one major apolipo-
protein each so the concentration of these apolipoproteins
is generally correlated with the concentrations of the
associated lipoproteins, although variation in size of the
lipoprotein particles can to some degree alter the correl-
ation between concentration of apolipoprotein and the
associated cholesterol [39]. In the present study, however,
LDL and HDL particle size were measured and it was ob-
served that the particles did not change their size during
the course of the study. The measurements of the main
apolipoproteins for LDL (ApoB100) and HDL (ApoA1)
revealed that the patterns for LDL and ApoB100 were
similar, and the same was the case for HDL and ApoA1.
These coherent patterns strengthen the evidence that the
observed reduction in total cholesterol and LDL-c and the
increase in HDL-c are biologically significant.
In a review published in 2006, Balk and co-workers
evaluated 21 studies on effects of fish oil and plant-
source omega-3 fatty acids on serum cholesterol and
other markers considered to be risk factors for develop-
ment of cardiovascular disease [40]. By combining the
data in the 21 studies they found clear and dose-related
effects of fish-oil only on triglyceride levels while there
was no effect on total cholesterol. HDL-c and LDL-c in-
creased slightly. The data for omega-3 from plants, i.e.,
alpha-linolenic acid (C18:3n3), were more unclear and
no conclusive evidence of effects on the serum bio-
markers was seen. In a meta-analysis published in 2012
and based on 20 studies including 68 680 patients, Rizos
et al. concluded that LC omega-3 PUFAs are not statisti-
cally significantly associated with major cardiovascular
outcomes across various patient populations [41]. This
publication did not specify the source of the omega-3 s
administered to the populations but given that the vast
majority of omega-3 products on the market originate
from fatty fish it can be assumed that most of the sub-
jects used fish oil. There is a lack of larger studies and
meta-analyses of effects of krill oil and results from indi-
vidual studies are equivocal with respect to effects on
cholesterols. Bunea at al. gave Neptune Krill oil (NKO)
to patients with hyperlipidemia at doses of 1–3 g/day for
90 days and observed dose-dependent effects on all main
blood lipids. The highest dose of 3 g/day reduced total
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cholesterol by 18%, LDL-c by 37% and triglycerides by
28% and at the same time increased HDL-c by as much
as 55% [42]. In a recently published randomized con-
trolled clinical trial, Lobraico and co-workers gave krill
oil containing 1 g omega-3 fatty acids to patients with
diabetes type-2 for 17 weeks and demonstrated that fol-
lowing treatment, the patients had significantly im-
proved endothelial function and increased HDL but no
effect was seen on LDL levels, neither relative to base-
line nor to a control population given olive oil [43].
Berge et al. (2014), giving krill oil up to 4 g/day for
12 weeks to subjects with borderline high or high serum
triglyceride levels did not see any significant effects on
cholesterols but observed a reduction in triglycerides
[44]. Interestingly, a recent randomized, cross-over study
from Cicero et al. compared the effects of 500 mg krill
oil given twice a day with those of 1000 mg omega-3
ethyl ester twice a day and found that although the ethyl
esters were more efficacious than krill oil in reducing tri-
glycerides, only krill oil was able to significantly increase
HDL-c and ApoA1 levels [45]. One reason for this dif-
ference in outcome might be the baseline level of blood
lipids in the studied populations because generally, the
more abnormal baseline levels of blood lipids the more
significant effects might be expected of the various lipid-
lowering treatments.
The main components of normal krill oil are around
40% phospholipids in addition to triglycerides, free fatty
acids and the natural antioxidant astaxanthin [46]. The
major part (>65%) of the omega-3 fatty acids in krill oil
is in the phospholipid fraction. Fish oil consists mainly
of triglycerides with which the omega-3 fatty acids are
associated. This variation in omega-3 fatty acid chemis-
try might cause a difference in important factors mediat-
ing effects on blood lipids like distribution to tissues,
distribution among the various lipoproteins in blood and
effects on regulators of lipid metabolism in the liver. In
addition, the main phospholipid in krill oil is phosphat-
idylcholine which is the main source of the essential nu-
trient choline in mammals. Choline has been shown to
influence cholesterol metabolism and transport [47] and
the administration of a combination of omega-3 fatty
acids and choline could potentially cause an additive or
synergistic, beneficial effect on the blood cholesterol
levels. Hence, when considering pharmacological effects
of LC omega-3 s it is necessary to specify the source and
chemical composition of the fatty acids administered. In
the present study, the omega-3 s were bound only in
phospholipids and this is a preparation basically different
from other forms of omega-3 s that have been investi-
gated previously for similar indications and it should not
be considered equivalent to natural krill oil.
The main conclusions from this work were based on
control-corrected values, where the original
measurements first were baseline-adjusted. This was
done to take full value of the data obtained in the con-
trol group which was equal in size to the treated group.
The control group was given the same vehicles as the
treated group and is therefore expected to correct for
any biological effects of the vehicles, ethanol and
PEG400, as well as for effects of the frequent handling
(dosing, weighing and blood sampling) of the animals
during the course of the study. However, when consider-
ing the absolute values obtained during the analysis of
the blood samples, the trends of reduced total choles-
terol, LDL-c and triglycerides and increased HDL-c were
obvious even without adjusting for the changes in the
control animals but the dose–response relationships
were more obvious when taking the control data into ac-
count, indicating that this could be the more relevant
way to interpret the data.
The most important limitation of the current study is
obviously the number of animals being included in the
experiments. While a group size of 3 animals allows
trends to be detected, statistical analyses are not mean-
ingful with this low number. Therefore, the data were
mainly used to assess trends in the various parameters
and statistics was limited to estimating standard error of
means in order to indicate the variation around the
mean values.
Conclusions
This study demonstrated that long-term treatment with
a novel and highly purified omega-3 rich phospholipid
preparation extracted from krill oil altered the blood
lipid profiles in dyslipidemic, diabetic non-human pri-
mates markedly and in a health-beneficial manner by re-
ducing total cholesterol, LDL-cholesterol and
triglycerides while it increased HDL-cholesterol. No ef-
fects were observed on lipoprotein particle size and dia-
betes parameters. There were no effects on coagulation
parameters, and commonly used biomarkers of liver and
kidney toxicity were unchanged. This preparation may
potentially be a useful therapy to normalize dyslipidemia
without significant side-effects, either alone as a single-
agent treatment or in combination with other therapies
like statins or PCSK9 inhibitors. In addition, the known
anti-inflammatory effects of the LC omega-3 fatty acids
EPA and DHA could further reduce the risk of develop-
ing atherosclerotic, cardiovascular diseases. However,
further pre-clinical studies are required to elucidate the
full potential and the mechanism(s) of action of this
preparation and to justify its entrance into clinical trials.
Methods
Test and control articles
The test article used was a preparation of 98% pure
phospholipids, extracted from krill oil originating from
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Antarctic krill (Euphausia superba) supplied by Aker
Biomarine, Oslo, Norway and formulated for oral ad-
ministration by adding 12.5% poly-ethylene glycol with a
MW of 400 (PEG400) and 3.5% absolute ethanol, hence
the test article contained 84% (840 mg/g) phospholipids.
Phospholipids from krill oil are rich in omega-3 fatty
acids and the final preparation contained 157 mg EPA
(C20:5n3)/g and 92 mg DHA (C22:6n3)/g. Gas-
chromatography analysis detected 23 fatty acids in the
end-product in addition to EPA and DHA, five of these
were present with an abundance of more than 1%
(10 mg/g): myristic acid (C14:0) 1.1%, palmitic acid
(C16:0) 13.2%, oleic acid (C18:1n9) 2.1%, cis-vaccenic
acid (C18:1n11) 3.1% and stearidonic acid (C18:4n3)
1.3%. Phosphatidylcholine comprised 90% of all phos-
pholipids in the preparation, and the choline moiety
constitutes 13% of the phosphatidylcholine molecule.
Dose levels given throughout the text refer to the dose
of phospholipids, i.e., a dose of 50 mg/kg/day means
50 mg of purified phospholipids/kg body weight/day.
Daily doses of EPA, DHA and choline are however spe-
cified in the tables presenting the results. The control
article was composed of 84% water, 12.5% PEG400 and
3.5% ethanol and by this, both the control and treated
animals received the same dose of the vehicles but for
the controls, the phospholipids were substituted by
water. To ease the administration, the test article was
warmed to ca. 35 °C and mixed with water just prior to
dosing to make an aqueous emulsion with low viscosity.
To keep consistency, the control article was treated
identical to the test article. The phospholipid formula-
tion used has been proven stable for at least 6 months.
Animals
Six type-2 diabetic and dyslipidemic cynomolgus mon-
keys (Macaca fascicularis) were selected for the study,
after screening a total of 34 animals. Inclusion criteria
were predefined and were related to diabetes parameters
(HbA1c, glucose and insulin) and blood lipid levels
(triglycerides, total cholesterol, LDL-c and HDL-c). The
animals included were defined diabetic and hyperlipid-
emic with reference to normal levels in this strain of mon-
keys housed at Crown Biosciences in Taicang, China. The
vital data and the individual screening values for the mon-
keys included in the study are detailed in Table 5.
The animals were housed individually in cages, in
rooms with a temperature of 20–23 °C, humidity 40–
70% and a 12 h dark/light cycle. They were fed a stand-
ard monkey diet containing crude protein (≥16%), crude
fat (≥4%), moisture (≤10%), ash (≤7%), fiber (≤4%),
calcium (0.8–1.2%) and phosphorus (0.6–0.8%). The
content of omega-3 fatty acids in the diet was not mea-
sured by the supplier (Beijing Keao Xieli Feed Co. Ltd.,
Beijing, P.R. China) and was therefore unknown. Care
and use of the animals were conducted in accordance
with all applicable assessments and accreditations of the
laboratory animal care (AAALAC) regulations and
guidelines. Crown bioscience institutional animal care
and use committee (IACUC) approved all animal proce-
dures used in the study. All the procedures related to
handling, care and treatment of the animals were per-
formed according to the guidelines approved by AAA-
LAC. After each handling (weighing, bleeding or
dosing), the animals were observed until they were able
to stand up and alert if they were anesthetized. At the
time of routine monitoring, the animals were checked
for any effects of the compound on their behavior such
as mobility, food and water consumption, body weight
gain/loss, and any other abnormal activities. Clinical ab-
normalities observed were recorded and reported. After
completion of the study the animals were returned to
the stock of diabetic monkeys held at Crown Biosciences
for a recovery period and following this they were
allowed to be used in other studies.
Administration of test and control articles
The control and test articles were given by gavage, 1 h
after the first feeding of the day. The control article was
Table 5 Vital data and results from the screening of the animals included in the study. The normal range values refer to values
measured in normal, non-diabetic cynomolgus monkeys housed at the laboratory where this study was conducted





TC LDL HDL TG Hb1Ac Glucose Insulin
(mg/dL) (mg/dL) (mg/dL) (mg/dL) (%) (mg/dL) (mIU/L)
Control Control no. 1 M 14 9.22 140 57.0 57.0 162 13.8 261 9.70
Control no. 2 M 15 10.0 103 48.0 38.0 55.0 10.2 234 22.4
Control no. 3 F 13 4.32 191 76.0 80.0 89.0 4.6 67 36.7
Treated Treated no. 1 M 14 8.30 188 74.0 60.0 269 17.5 157 200
Treated no. 2 F 21 7.34 256 162 40.0 400 10.1 224 56.1
Treated no. 3 M 20 10.8 128 49.0 61.0 50.0 5.90 109 51.8
Normal range 97 ± 4 35 ± 3 30–55 14–88 ≤5 40–75 20–50
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administered at the same volume/kg as the test article.
For the first 4 weeks, a phospholipid dose of 50 mg/kg/
day was given, the next 4 weeks the dose was 150 mg/
kg/day and for the last 4 weeks 450 mg/kg/day. Dosing
volumes were based on body weights recorded bi-weekly
after overnight fasting. When converted to human
equivalent dose (HED) these doses were equivalent to
approximately 1, 3 and 10 g/day, respectively, to an adult
person of 70 kg.
The dosing was done by inserting a naso-/oral-/gastric
tube into the stomach and injecting the correct volume as
a bolus. The tube was then flushed with 5 mL lukewarm
water to assure the administration of the entire volume.
Following completion of the 12-week dosing period,
the animals were followed for 8 more weeks to investi-
gate how selected parameters developed upon cessation
of treatment. During these 8 weeks, neither the control
nor the test article was given but blood samples were
drawn bi-weekly and prepared for analysis.
Blood sampling and analysis
After overnight fasting and before dosing, blood was
sampled at baseline, i.e., before starting the treatment
with the control or test item, and either weekly, bi-
weekly or every 4 weeks during the 12-week dosing
period for analysis of the experimental parameters.
Weekly, the following primary parameters were analyzed
in blood serum by a Siemens Advia-2400 Clinical Chem-
ical System: Total cholesterol, LDL cholesterol (LDL-c),
HDL cholesterol (HDL-c), triglycerides, apolipoprotein
B100 (ApoB100), apolipoprotein A1 (ApoA1), apolipo-
protein B48 (ApoB48), apolipoprotein C3 (ApoC3) and
apolipoprotein E (ApoE). Non-HDL cholesterol (Non-
HDL-c) was estimated by subtracting HDL-c from total
cholesterol. Parameters analyzed bi-weekly in blood:
Glycated hemoglobin (Hb1Ac, by ion-exchange HPLC),
glucose (by Siemens Advia-2400), insulin (by Siemens
Advia Centaur XP) and C-reactive protein (C-rp, by
Siemens Advia-2400). Triglycerides and lipoproteins, in-
cluding concentration and size of LDL and HDL parti-
cles, were measured bi-weekly in blood plasma by nuclear
magnetic resonance (NMR) spectroscopy. The following
parameters were measured bi-weekly in plasma by Lumi-
nex kits: soluble intercellular adhesion molecule-1 (sIC
AM-1), soluble vascular adhesion molecule-1 (sVCAM-
1), P-selectin, monocyte chemotactic protein-1 (MCP-
1) and macrophage colony-stimulating factor (M-CSF).
Fatty acids in erythrocyte membranes, including the
omega-3 index [27] were also measured bi-weekly by a
previously described method based on formation of
fatty acid methyl esters and analysis by gas chromatog-
raphy with flame ionization detection [48] (only the
omega-3 index values are reported here, the time-
course of the 24 individual fatty acids analyzed is
reported elsewhere). At baseline and every 4 weeks
during the dosing period, just before increasing the
dose to the next level, the following parameters were
measured: aspartate aminotransferase (AST), alkaline
phosphatase (ALT), blood urea nitrogen (BUN), cre-
atinine, uric acid (UA), cystatin-C, prothrombin time
(PT), activated prothrombin time (APTT), thrombin
time (TT), white blood cell concentration (WBC, total
and differential counting), red blood cell concentration
(RBC), hematocrit (Hct), mean cellular volume of RBC
(MCV), mean cellular hematocrit (MCH) and mean
corpuscular hemoglobin concentration (MCHC).
Plasma sampled at baseline and at 1, 2, 4, 8, 12, 24
and 48 h and 7, 14 and 21 days after the first dose of
each dose level, and in addition at 28 days after the first
dose of the highest dose level of 450 mg/kg/day, were
analyzed for the determination of EPA, DPA and DHA
concentrations by a liquid chromatography tandem
mass-spectrometry (LC-MS/MS) method specifically de-
veloped for this purpose. This method will be published
separately but in brief, plasma samples were prepared
using protein precipitation followed by alkaline hydroly-
sis to release the fatty acids from phospholipids, triglyc-
erides and other lipid classes to the free form.
Deuterated EPA (EPA-d5) and DHA (DHA-d5) were
used as internal standards. The determination of fatty
acid concentrations, which were the sum of endogenous
EPA, DPA and DHA and these fatty acids stemming
from the administered compound, was done by MS/MS
(PE Sciex API 4000) using Turbolonspray in negative
ion, multiple reaction monitoring mode.
The blood samples taken during the 8 weeks after end
of treatment were analyzed for the following parameters:
total cholesterol, LDL-c, HDL-c, triglycerides, apoB100,
ApoA1, LDL particle size as well as omega-3 index and
plasma concentrations of EPA, DPA and DHA. The
methods applied were the same as listed above.
In addition to the above parameters, blood samples
were taken bi-weekly for analysis of the following endo-
cannabinoids and endocannabinoid-type compounds in
plasma: anandamide, 2-arachidonoylglyceride, EPA etha-
nolamide, DHA ethanolamide, palmitoyl ethanolamide
and oleoyl ethanolamide. The results of these analyses
will be published separately, together with the results of
the fatty acid concentrations in erythrocyte mebranes.
Data presentation and statistics
The data tabulated for the main parameters (choles-
terols, apolipoproteins and triglycerides) are firstly abso-
lute arithmetic mean of each parameter in the control
and treated group, with standard error of the mean
(SEM) to indicate the variability in the groups, secondly
the control adjusted changes. Control adjusted values
were calculated by normalizing all values measured
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during and after treatment to the baseline values, i.e., by
defining the baseline value in each animal as 100% and
then calculate the change relative to baseline. The result-
ing mean at each time-point in the treated group is then
subtracted from the mean of corresponding time-points
in the control group, giving the control-adjusted change
at each data-point. For diabetes and safety parameters,
mean and SEM values are presented.
Given the low number of animals in each of the two
groups, comparison of effects based on statistical criteria
was not done. Despite the low number of animals in
each group, arithmetic mean rather than median was
used to describe the group changes in the measured pa-
rameters at each time-point, both for absolute values
and for values normalized to baseline.
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